Ignite Creation Date:
2024-05-06 @ 9:12 AM
Last Modification Date:
2024-10-26 @ 12:11 PM
Study NCT ID:
NCT02923856
Status:
UNKNOWN
Last Update Posted:
2019-02-19
First Post:
2016-08-23
Brief Title:
A Multi-center Study for Eradication of Helicobacter Pylori With Triple Therapy Using Clarithromycin
Sponsor:
Sanmen Peoples Hospital
Organization:
Sanmen Peoples Hospital
Study Overview
Official Title:
A Multi-center Study for Eradication of Helicobacter Pylori With Triple Therapy Based on Accurate Susceptibility Testing of Clarithromycin
Status:
UNKNOWN
Status Verified Date:
2018-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
As the resistant rate of the Helicobacter pylori to some common antibiotics was risingthe eradication rate of the Helicobacter pylori with the standard triple therapy failed to exceed 70 in Chinaand had to drop out of the first-line treatment recommendations However with the increase of treatment time patients burden adverse reactions of antibiotics or proton pump inhibitor PPI will also increase Resistance to clarithromycin is the major cause of the failure to eradicate Helicobacter pylori But in terms of population there are still more than 70 of the patients with clarithromycin sensitive Under the guidance with susceptibility test7-day standard triple therapy could be used In this study investigators will select the patients with infection of H pylori and with clarithromycin sensitive Eradication of Helicobacter pylori with triple therapy based on accurate susceptibility testing of clarithromycin will be studied The treatment time will be assigned into 7 days10 days and 14 days groups Then investigators will perform a sequencing for failed treatment patients in groups such as drug resistance gene mutation phenotype and genotype Finally investigators will compare the differences between the patients with triple therapy and traditional quadruple therapyThe incidence of adverse effects in the eradicate treatment will reduce at least 10 and avoid patients unnecessary economic losses at least 400RMB per person
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None